The Only Biotech Stock to Own for 2011

Filed in BP, Gold, Gold Market, o, obama, target by on January 25, 2011 0 Comments

Take a look at the following chart: Last week, my favorite biotech stock— Anavex (AVXL-OTCBB) — made a two-and-a-half year high, reaching an intra-day high of $4.75. Readers who’ve followed my advice are sitting on at least a 50% gain… in most cases, even more. I’ve been urging (heck, I’ve been begging) readers to get a position in Anavex before it’s too late. Well my friend, that train is starting to leave the station, as Anavex has been on the receiving end of two excellent developments since the start of the year. ~~SIGNUP_WD~~ The first came as Obama signed into law the National Alzheimer’s Project Act (NAPA) . NAPA creates, for the first time, a coordinated national strategy to confront one of America’s most feared and costly diseases— a disease that will only plague more baby boomers as they age. Given the scale of the Alzheimer epidemic and the growing number of Americans directly affected every single day, NAPA will provide an essential framework within the government that recognizes the Alzheimer crisis is no longer emerging… but is here. Alzheimer’s — or the Grey Plague, as we’ve dubbed it — is a disease with no known cure. Robbed of memory, those who contract it die a slow and agonizing death while loved ones watch in horror. Each year the numbers of lives destroyed by it grow. And it’s easy to see why… The United States has a rapidly aging population. An estimated 7,000 boomers will turn 65 each day in 2011. Think about that for a minute… The current costs associated with AD are well into the billions. It’s no big surprise, then, that Alzheimer’s looms large on the radar screens of the major biotech companies. It’s a giant— and growing — market. One which is attracting more and more money in search of a cure. Anavex, just now entering Phase I, is in a unique position to attract the attention of the entire industry. In fact, it’s already started to do just that… You see, the second big development for Anavex came earlier in January when Alzheimer’s Weekly named ANAVEX 2-73 the promising clinical trial for 2011. According to the press release: Hoboken, NJ – January 6, 2011 — Anavex Life Sciences Corp. (“Anavex”, AVXL:OB) announced today that ANAVEX 2-73 has been named 2010’s “most promising trial drug” by the editorial staff at Alzheimer’s Weekly. The publication selected the ANAVEX 2-73 trial from a field of over 100 trials that treat dementias such as Alzheimer’s and following the review of more than 10,000 articles. Staffers and clinical experts of Alzheimer’s Weekly said that Anavex stands out when scrutinized against their key criteria for potential treatments, including small molecule drugs, oral bioavailability, possibility for disease modification, targeting multiple pathways, near-term availability and entering human trials. “It is extremely rewarding for our team to receive such significant and independent third-party recognition for ANAVEX 2-73 and our unique approach in Alzheimer’s disease,…

Visit link:
The Only Biotech Stock to Own for 2011

Tags: , , , , , , , , , , , ,

About the Author ()

Leave a Reply

Your email address will not be published. Required fields are marked *